Proteostasis Therapeutics's stock plunges to pace all decliners after results of CF treatment trial disappoint

生物制药公司 Proteostasis Therapeutics 新药研发举步维艰,导致股价大跌

2019-03-27 15:44:00 MarketWatch

本文共484个字,阅读需2分钟

By Shares of Proteostasis Therapeutics Inc. PTI, -59.19% plunged 58% on heavy volume in morning trade Monday, enough to pace all decliners trading on major U.S. exchanges, after biopharmaceutical company announced results from a phase 1 study of its cystic fibrosis (CF) treatment. Trading volume ballooned to 7.6 million shares, compared with the full-day average of 1.2 million shares. The company said the increase in ppFEV1 at day 14 of a statistically significant 5 percentage points versus baseline was observed in the 600 milligram PTI-801 cohort. Analyst Geoffrey Porges at SVB Leerink said the results CF did not meet the efficacy of Vertex Pharmaceuticals Inc.'s VRTX, +1.43% medicines, as that 5% was below the 13%-14% hurdle established by Vertex. Porges believes the results of Proteostasis' trial removes the final "long-shot competitor" to Vertex's CF portfolio. Vertex shares gained 1.0% in morning trade. Proteostasis's stock has lost 66.3% over the past 12 months, while Vertex shares have rallied 13.8% and the S&P 500 SPX, -0.04% has gained 7.8%.
由。 Protestossis Therapeutics Inc 。 PTI ,-59.19% 周一早盘交易中,生物制药公司公布了其囊性纤维化( CF )治疗的第一阶段研究结果,该公司股价大跌58%,足以赶上美国主要交易所的所有下跌。成交量激增至760万股,而全天平均为120万股。该公司说,在14天的 ppFEV1增加了5个百分点,与基线相比,在600毫克的 PTI-801队列中观察到。SVB Leerink 公司的分析师 Geoffrey Porges 说, CF 的结果不符合福泰(Vertex)制药公司的疗效 VRTX ,+1.43% 药物,因为5%低于由福泰(Vertex)建立的13%-14%的门槛。Porges 认为, Protestosta 的试验结果消除了最终的“长期竞争对手”福泰(Vertex)的 CF 组合。福泰(Vertex)股价在早盘交易中上涨1.0%。在过去的12个月中, Protostex 的股价下跌了66.3%,福泰(Vertex)的股价上涨了13.8%,标准普尔500指数也上涨了500 SPX ,-0.04% 上涨了7.8%。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文